BioAxone is a biopharmaceutical company that develops  transformative treatments for neurotrauma and neurovascular disorders. The company has developed innovative therapies based on a deep understanding of axon regeneration and neuronal signaling pathways.

  • BioAxone has a experience in bringing a biologic drug from lab bench to Phase 3 clinical trials for treatment of acute spinal cord injury. The lead compound, BA-210 inactivates Rho, a small GTPase protein that is a key target to switch neurons into a pro-regenerative state.¬† This compound is available for out-licensing.
  • A second drug development program for treatment of spinal cord injury is focused on the intrinsic barriers to regeneration brought on by neuronal aging. BioAxone has developed a novel self-delivering RNA interference compound that reduces expression of PTEN, a protein that blocks axon regeneration in adult neurons. This compound is in preclinical testing.
  • BioAxone has out-licensed a portfolio of ROCK-2 selective Rho kinase inhibitors. The lead compound is an oral kinase inhibitor for treatment of neurovascular disorders.